© 2025 HSP News Service, L.L.C.
In an analysis in the CLEOPATRA trial population reported in the Journal of Clinical Oncology, Baselga et al found that HER2 was the only biomarker suitable for use in selecting patients for first-line pertuzumab (Perjeta)/trastuzumab (Herceptin)-based treatment in patients with HER2-positive...
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Reported by Lange et al in Cancer, the findings suggest that cancer screening guidelines might ...
Earlier planned joint analyses of outcomes in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and North Central Cancer Treatment Group (NCCTG) N9831 trial showed that adding trastuzumab (Herceptin) to adjuvant chemotherapy improved disease-free survival and overall...
Using genomic sequencing data on all currently known genetic alterations in breast cancer, it is possible to identify a woman’s genetic risk for the disease, and this approach can bring greater gains in disease prevention than previously estimated, according to a study reported by Sieh et al...
Researchers at VTT Technical Research Centre of Finland, the University of Turku, Finland, and the University of Oslo, Norway, have discovered a previously unknown molecular-level mechanism that may partly explain the increased growth of cancer cells. The study, published in the British Journal of...
Neratinib is an irreversible pan-tyrosine kinase inhibitor with activity against HER1, HER2, and HER4. In a phase I/II trial reported in the Journal of Clinical Oncology, Saura et al found that the combination of neratinib and capecitabine exhibited high activity in patients with trastuzumab...
For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The...
The U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application for the expanded use of technetium 99m tilmanocept (Lymphoseek Injection) for lymphatic mapping in solid tumors and for adding sentinel lymph node detection for breast cancer and melanoma to the approved...
Regardless of age at diagnosis, type of treatment, tumor grade or size, and tumor histology, black and Hispanic women had a higher risk of second ipsilateral breast tumors than did white women after ductal carcinoma in situ, according to the results of a large registry study presented by Liu et al...
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Pfizer’s New Drug Application for palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor–positive, HER2-negative advanced breast cancer...
In breast cancer patients under the age of 40, positron-emission tomography/computed tomography (PET/CT) scanning may provide accurate clinical staging for stage IIB and III disease, according to the study findings presented by Riedl et al in The Journal of Nuclear Medicine. The utilization of...
In the phase III TANIA trial reported in The Lancet Oncology, von Minckwitz et al found that adding bevacizumab (Avastin) to chemotherapy in second-line treatment improved progression-free survival after first-line bevacizumab plus chemotherapy in patients with HER2-negative locally recurrent or...
Regulatory approval of bevacizumab (Avastin) plus docetaxel in metastatic breast cancer was withdrawn in Europe in February 2011 and in the United States in November 2011. The phase III IMELDA trial comparing maintenance capecitabine/bevacizumab vs bevacizumab after first-line bevacizumab/docetaxel ...
A recently reported U.S. population-based case-control study in women aged 55 to 74 years indicated that current use of calcium channel blockers for ≥ 10 years was associated with increased risk of ductal breast cancer (odds ratio [OR] = 2.4) and lobular breast cancer. In a Swedish case-control...
In the Cancer and Leukemia Group B (CALGB) 70103 study, comorbidity was associated with shorter overall survival among older women with early-stage breast cancer and good functional status receiving adjuvant chemotherapy. “The presence of four or more conditions appeared to be a threshold for ...
In a Dutch study reported in the Journal of the National Cancer Institute, Boekel et al found no increase in risk of cardiovascular mortality among 5-year survivors of ductal carcinoma in situ (DCIS) compared with the general population. Among DCIS patients, risk of cardiovascular events did not...
In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...
In a randomized study reported in the Journal of the National Cancer Institute, Shike et al found that soy supplementation resulting in high genistein levels was associated with overexpression of the tumorigenic growth factor receptor FGFR2 and genes that drive cell cycle and proliferation...
In a study reported in the Journal of Clinical Oncology, Loibl et al found that PIK3CA mutation was associated with lower pathologic complete response rate in patients with HER2-positive breast cancer receiving trastuzumab (Herceptin), lapatinib (Tykerb), or both in addition to neoadjuvant...
In a study reported in the Journal of the National Cancer Institute, Prat et al found that there was little difference in downstream gene or protein expression according to intrinsic breast cancer subtypes among clinical HER2-positive vs -negative breast cancers and that clinical HER2 status did...
A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented at the American Society for Radiation...
In the phase III ROSE/TRIO-12 trial, reported in the Journal of Clinical Oncology, Mackey et al found no significant improvement in investigator-assessed progression-free survival by adding the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to first-line docetaxel in women with...
In a study reported in the Journal of the National Cancer Institute, Portschy et al found an absolute 20-year overall survival difference of < 1% with contralateral prophylactic mastectomy in women with stage I or II breast cancer without BRCA mutation. The authors had hypothesized that the...
In a study reported in JAMA Surgery, Morrow et al found that breast reconstruction after mastectomy for breast cancer largely reflects patient demand, with the majority of women being satisfied with the decision-making process. However, black women were significantly less likely to have...
In a retrospective study reported in JAMA Surgery, Black et al found that the sentinel lymph node biopsy rate was lower and risk for lymphedema higher in black vs white women with early-stage breast cancer in the Medicare population. Study Details The study used the Surveillance, Epidemiology,...
When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...
An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation. These...
Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....
A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented at the 2014 Breast...
Despite conjecture in the lay media that wearing a bra may be a risk factor for breast cancer based on the potential for bras to interfere with lymph circulation and drainage, hampering the removal of waste and toxins, there were few scientific studies investigating the issue. Now, a new study by...
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or unknown HER2 status breast cancer. The guideline is published in the Journal of Clinical Oncology. In formulating the consensus...
A survey of 150 women newly diagnosed with breast cancer provides new insight into factors that influence women’s decisions to undergo contralateral prophylactic mastectomy. This is one of the first studies to look at women’s breast surgery preferences prospectively, before they undergo ...
Results from a large population-based study of 189,734 women diagnosed with early-stage breast cancer in California show the percentage opting for a bilateral mastectomy has increased substantially over the past decade even though the procedure was not associated with a lower risk of death than...
A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....
A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...
An analysis of data from 12 large clinical trials found that the cancer’s pathologic response to neoadjuvant chemotherapy and tumor subtype are strong predictors of locoregional breast cancer recurrence. According to the researchers, the study showed that these two predictors may be more...
A retrospective review of records at an academic cancer center in Ontario, Canada, found that referrals for genetic counseling and the rates of genetic testing performed almost doubled over the 6-month period after Angelina Jolie announced she underwent a preventive double mastectomy because she...
Although studies have shown that women with a false-positive result from mammography screening have an increased risk of developing breast cancer later in life compared with women who only have negative results, a new Danish study examined how much of the excess risk was due to misclassification...
The ACOSOG Z0011/Alliance trial showed that axillary lymph node dissection provides no benefit over sentinel lymph node biopsy in patients with breast cancer with one or two positive sentinel lymph nodes undergoing lumpectomy, radiotherapy, and systemic therapy. In an analysis reported in the...
In a study reported in the Journal of Clinical Oncology, Tworoger et al found that inclusion of endogenous hormone levels in the Gail and Rosner-Colditz risk scores improved prediction of postmenopausal invasive breast cancer. Study Details The study involved 437 patients with breast cancer and...
In a study reported in JAMA Surgery, Abt et al found that neoadjuvant chemotherapy is safe in women with breast cancer undergoing mastectomy with or without immediate breast reconstruction. Neoadjuvant chemotherapy was an independent predictor of reduced 30-day postoperative morbidity in women...
Observational studies have suggested a potential effect of bisphosphonate treatment for osteoporosis in reducing risk of breast cancer in postmenopausal women. However, an analysis of the randomized FIT trial of alendronate and HORIZON-PFT trial of zoledronic acid reported in JAMA Internal Medicine ...
BluePrint in combination with MammaPrint molecular subtyping reclassified more than 20% of breast cancer patients into a different subgroup compared with conventional assessment, according to the results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). In Annals of Surgical...
The phase III NeoALTTO trial showed a significantly improved pathologic complete response rate with lapatinib (Tykerb) plus trastuzumab (Herceptin) vs either alone in women with HER2-positive early breast cancer. As reported in The Lancet Oncology by de Azambuja et al, the combination was not...
In a study reported in a letter to The New England Journal of Medicine, Dreijerink et al in the International Breast Cancer in MEN1 Study Group identified a high risk of breast cancer in women with multiple endocrine neoplasia type 1 (MEN1). MEN1 is caused by germline mutations in the MEN1...
Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. Data from a new study finds that overweight and obese women who regularly used aspirin or other...
Postmenopausal women who in the previous 4 years had undertaken the equivalent of at least 4 hours of walking per week had a 10% decreased risk of invasive breast cancer compared with women who were less active, according to a new study. The findings suggest that regular physical activity, even of...
In the phase II Cancer and Leukemia Group B (CALGB) 40603/Alliance trial reported in the Journal of Clinical Oncology, Sikov et al found that the addition of carboplatin or bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rate in...
In a study reported in The New England Journal of Medicine, Antoniou et al identified lifetime risk of breast cancer in families with germline loss-of-function mutations in PALB2. Estimated cumulative risk among female mutation carriers was 14% by 50 years of age and 35% by 70 years of age....
Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine have reported new information about the genetic alterations that may contribute to the development of a breast cancer subtype typically associated with more aggressive forms of the disease and higher recurrence...